<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596191</url>
  </required_header>
  <id_info>
    <org_study_id>2014-10</org_study_id>
    <nct_id>NCT02596191</nct_id>
  </id_info>
  <brief_title>Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers</brief_title>
  <acronym>CMT-TOOLS</acronym>
  <official_title>Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-year follow-up study of a cohort of 60 CMT1A patients. The objective is to&#xD;
      identify markers allowing to better understand the phenotypic variability observed on&#xD;
      patients with CMT1A, to identify predictive markers of the disease's progression and to&#xD;
      provide validated measurement tools that can be used as outcome measures in future clinical&#xD;
      trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Anticipated">December 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of functional scores</measure>
    <time_frame>3 months, 12 months and 24 months</time_frame>
    <description>several functional scores to evaluate the severity and the progression of the disease will be performed and compared (CMTNDS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of functional scores</measure>
    <time_frame>3 months, 12 months and 24 months</time_frame>
    <description>several functional scores to evaluate the severity and the progression of the disease will be performed and compared (CMTNS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of functional scores</measure>
    <time_frame>3 months, 12 months and 24 months</time_frame>
    <description>several functional scores to evaluate the severity and the progression of the disease will be performed and compared (CMTNS2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of functional scores at</measure>
    <time_frame>3 months, 12 months and 24 months</time_frame>
    <description>several functional scores to evaluate the severity and the progression of the disease will be performed and compared (ONLS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Walkin test</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>Use of connected soles for walking test (Digitsole)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Charcot-Marie-Tooth Disease Type 1A</condition>
  <arm_group>
    <arm_group_label>patients with mild CMT 1A disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Charcot-Marie-Tooth Neuropathy Score between 1 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with moderate CMT 1A disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Charcot-Marie-Tooth Neuropathy Score between 11 and 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with severe CMT 1A disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Charcot-Marie-Tooth Neuropathy Score ≥21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical evaluation</intervention_name>
    <arm_group_label>patients with mild CMT 1A disease</arm_group_label>
    <arm_group_label>patients with moderate CMT 1A disease</arm_group_label>
    <arm_group_label>patients with severe CMT 1A disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electrophysiological record</intervention_name>
    <arm_group_label>patients with mild CMT 1A disease</arm_group_label>
    <arm_group_label>patients with moderate CMT 1A disease</arm_group_label>
    <arm_group_label>patients with severe CMT 1A disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle MRI</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>patients with mild CMT 1A disease</arm_group_label>
    <arm_group_label>patients with moderate CMT 1A disease</arm_group_label>
    <arm_group_label>patients with severe CMT 1A disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples analysis</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>patients with mild CMT 1A disease</arm_group_label>
    <arm_group_label>patients with moderate CMT 1A disease</arm_group_label>
    <arm_group_label>patients with severe CMT 1A disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CMT 1A disease&#xD;
&#xD;
          -  Diagnosis of CMT 1A confirmed by genotyping (duplication of the 17p11.2 region)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from co-morbidity at the origin of peripheral neuropathy (diabetes,&#xD;
             hypothyroidism, renal insufficiency, drugs...) or muscle, articular, rheumatological&#xD;
             disease&#xD;
&#xD;
          -  With HIV or cancer&#xD;
&#xD;
          -  With a significant progressive disease in the previous month&#xD;
&#xD;
          -  With a contra-indication for MRI&#xD;
&#xD;
          -  With a dislocation, fracture, or recent surgery (less than 6 months before inclusion)&#xD;
&#xD;
          -  with alcohol or psychoactive substances abuse&#xD;
&#xD;
          -  Treated by an anti-inflammatory drug over the past four weeks&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Homeless patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle Desalbres</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahram ATTARIAN, MD</last_name>
    <email>shahram.attarian@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahram Attarian, MD</last_name>
      <email>shahram.attarian@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Gui de Chauliac, CHU MONTPELLIER</name>
      <address>
        <city>Montpellier</city>
        <zip>34285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Camu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

